Zoetis Inc. (ZTS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.06B USD | Liabilities, Current |
| Cash and equivalents | 1.48B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.57B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 2.57B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.06B | $1.48B | (m) | $1.57B | $2.57B | (m) |
| 2026-03-31 | (m) | $2.05B | $1.94B | (m) | $1.51B | $2.55B | (m) |
| 2025-12-31 | (m) | $2.23B | (m) | (m) | $1.59B | $2.43B | (m) |
| 2025-09-30 | (m) | $1.81B | $2.08B | (m) | $1.54B | $2.46B | (m) |
| 2025-06-30 | (m) | $3.37B | $1.44B | (m) | $1.54B | $2.44B | (m) |
| 2025-03-31 | (m) | $3.38B | $1.72B | (m) | $1.36B | $2.37B | (m) |
| 2024-12-31 | (m) | $3.41B | (m) | (m) | $1.32B | $2.31B | (m) |
| 2024-09-30 | (m) | $1.70B | $1.71B | (m) | $1.41B | $2.42B | (m) |
| 2024-06-30 | (m) | $1.80B | $1.57B | (m) | $1.38B | $2.45B | (m) |
| 2024-03-31 | (m) | $1.91B | $1.98B | (m) | $1.29B | $2.65B | (m) |
| 2023-12-31 | (m) | $1.89B | (m) | (m) | $1.30B | $2.56B | (m) |
| 2023-09-30 | (m) | $1.61B | $1.75B | (m) | $1.26B | $2.74B | (m) |
| 2023-06-30 | (m) | $1.77B | $1.72B | (m) | $1.32B | $2.70B | (m) |
| 2023-03-31 | (m) | $1.92B | $2.11B | (m) | $1.19B | $2.56B | (m) |
| 2022-12-31 | (m) | $3.17B | (m) | (m) | $1.22B | $2.35B | (m) |
| 2022-09-30 | (m) | $2.88B | $2.51B | (m) | $1.19B | $2.30B | (m) |
| 2022-06-30 | (m) | $3.05B | $2.65B | (m) | $1.29B | $2.21B | (m) |
| 2022-03-31 | (m) | $3.03B | $3.13B | (m) | $1.22B | $2.06B | (m) |
| 2021-12-31 | (m) | $1.80B | (m) | (m) | $1.13B | $1.92B | (m) |
| 2021-09-30 | (m) | $1.47B | $3.27B | (m) | $1.15B | $1.88B | (m) |
| 2021-06-30 | (m) | $2.09B | $3.66B | (m) | $1.17B | $1.80B | (m) |
| 2021-03-31 | (m) | $2.07B | $3.60B | (m) | $1.13B | $1.70B | (m) |
| 2020-12-31 | (m) | $2.17B | (m) | (m) | $1.01B | $1.63B | (m) |
| 2020-09-30 | (m) | $2.40B | $3.65B | (m) | $1.01B | $1.63B | (m) |
| 2020-06-30 | (m) | $1.81B | $3.35B | (m) | $984.00M | $1.58B | (m) |
| 2020-03-31 | (m) | $1.72B | $1.95B | (m) | $965.00M | $1.48B | (m) |
| 2019-12-31 | (m) | $1.81B | (m) | (m) | $1.09B | $1.41B | (m) |
| 2019-09-30 | (m) | $1.05B | $1.81B | (m) | $1.03B | $1.44B | (m) |
| 2019-06-30 | (m) | $1.07B | $1.75B | (m) | $994.00M | $1.40B | (m) |
| 2019-03-31 | (m) | $1.08B | $1.73B | (m) | $970.00M | $1.36B | (m) |
| 2018-12-31 | (m) | $1.22B | (m) | (m) | $1.04B | $1.39B | (m) |
| 2018-09-30 | (m) | $1.00B | $1.29B | (m) | $929.00M | $1.44B | (m) |
| 2018-06-30 | (m) | $967.00M | $1.56B | (m) | $973.00M | $1.42B | (m) |
| 2018-03-31 | (m) | $1.00B | $1.65B | (m) | $943.00M | $1.44B | (m) |
| 2017-12-31 | (m) | $1.09B | $1.56B | (m) | $998.00M | $1.43B | (m) |
| 2017-10-01 | (m) | $1.75B | $1.98B | (m) | $1.01B | $1.49B | (m) |
| 2017-07-02 | (m) | $1.78B | $705.00M | (m) | $975.00M | $1.50B | (m) |
| 2017-04-02 | (m) | $1.73B | $629.00M | (m) | $954.00M | $1.53B | (m) |
| 2016-12-31 | (m) | $1.12B | $727.00M | (m) | $913.00M | $1.50B | (m) |
| 2016-10-02 | (m) | $1.04B | $651.00M | (m) | $915.00M | $1.56B | (m) |
| 2016-07-03 | (m) | $1.04B | $658.00M | (m) | $888.00M | $1.52B | (m) |
| 2016-04-03 | (m) | $1.16B | $675.00M | (m) | $908.00M | $1.46B | (m) |
| 2015-12-31 | (m) | $1.78B | $1.15B | (m) | $937.00M | $1.47B | (m) |
| 2015-09-27 | (m) | $1.66B | $592.00M | (m) | $1.04B | $1.40B | (m) |
| 2015-06-28 | (m) | $1.57B | $544.00M | (m) | $993.00M | $1.42B | (m) |
| 2015-03-29 | (m) | $1.37B | $559.00M | (m) | $905.00M | $1.35B | (m) |
| 2014-12-31 | (m) | $1.09B | $882.00M | (m) | $980.00M | $1.29B | (m) |
| 2014-09-28 | (m) | $998.00M | $598.00M | (m) | $1.06B | $1.39B | (m) |
| 2014-06-29 | (m) | $1.06B | $578.00M | (m) | $1.10B | $1.34B | (m) |
| 2014-03-30 | (m) | $1.13B | $506.00M | (m) | $1.10B | $1.32B | (m) |
| 2013-12-31 | (m) | $1.42B | $610.00M | (m) | $1.14B | $1.29B | (m) |
| 2013-09-29 | (m) | $1.31B | $389.00M | (m) | $1.11B | $1.29B | (m) |
| 2013-06-30 | (m) | $1.32B | $369.00M | (m) | $1.14B | $1.26B | (m) |
| 2013-03-31 | (m) | $1.29B | $468.00M | (m) | $861.00M | $1.12B | (m) |
| 2012-12-31 | (m) | $1.12B | $317.00M | (m) | $900.00M | $1.34B | (m) |
| 2012-09-30 | (m) | (m) | $133.00M | (m) | (m) | (m) | (m) |
| 2012-07-01 | (m) | (m) | $106.00M | (m) | (m) | (m) | (m) |
| 2012-04-01 | (m) | (m) | $113.00M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $79.00M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $63.00M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |